Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Not applicable Interventional

Effect of Flourish HEC Vaginal Care System on BV Recurrence and the Vaginal Microbiome

NCT05701722
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Flourish HEC Vaginal Care System
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

NCT01270659
View directory record Official record
Conditions
Pain
Interventions
Fentanyl, oxycodone/acetaminophen
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

NCT00309712
View directory record Official record
Conditions
Type II Diabetes Mellitus, Mixed Dyslipidemia
Interventions
fenofibrate 160 mg and placebo, simvastatin 20 mg and placebo, fenofibrate 160 mg and simvastatin 20 mg
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

NCT00322465
View directory record Official record
Conditions
Urethritis
Interventions
Doxycycline, Placebo, Tinidazole, Azithromycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure

NCT00280072
View directory record Official record
Conditions
Kidney Failure, Acute
Interventions
Renal Assist Device
Device
Lead sponsor
RenaMed Biologics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

NCT03621657
View directory record Official record
Conditions
Clostridium Difficile Infection, C.Difficile Diarrhea, CDI
Interventions
Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 22, 2026, 5:58 AM EDT
Enrolling by invitation No phase listed Observational

Health eHeart BEAT-AFib - Health eHeart Biomarkers of Early Atrial Transformation in Atrial Fibrillation

NCT04404465
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

NCT01920711
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

NCT02340234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
Biological · Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 22, 2026, 5:58 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

NCT02794519
View directory record Official record
Conditions
Asthma
Interventions
Sirukumab, Placebo, Rescue medication
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Long Beach, California • Aventura, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

NCT02066181
View directory record Official record
Conditions
Desmoid Fibromatosis
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Sorafenib Tosylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
149
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arroyo Grande, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

NCT00040677
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Low Dose ICA-17043, High dose ICA-17043, Placebo
Drug
Lead sponsor
Icagen
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 22, 2026, 5:58 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities

NCT02513407
View directory record Official record
Conditions
Healthy Subject
Interventions
Behavioral Dietary Intervention, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Questionnaire Administration
Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed No phase listed Observational

Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer

NCT00295945
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Pain, Perioperative/Postoperative Complications, Sarcoma
Interventions
fentanyl citrate, hydromorphone hydrochloride, ropivacaine hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04566445
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women

NCT00125983
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02886494
View directory record Official record
Conditions
Alzheimer's Disease or Vascular Dementia
Interventions
BAC treatment, Matched vehicle
Drug
Lead sponsor
Charsire Biotechnology Corp.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Tempe, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Not applicable Interventional Results available

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

NCT05523154
View directory record Official record
Conditions
Benign Pancreatic Neoplasm, Malignant Pancreatic Neoplasm
Interventions
Biospecimen Collection, Laboratory Procedure, Nanopore Sequencing
Procedure · Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00286494
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and pioglitazone, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

NCT02685605
View directory record Official record
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 5:58 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

NCT02281773
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo, BI 498306 25 mg QD, BI 409306 10 mg QD
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 22, 2026, 5:58 AM EDT